Question special

Most think that the CVD benefit of statins is entirely (or largely) explained by its LDL-c lowering effect while some argue that 'pleiotropic' effects (e.g. anti-inflammatory effects) are important.

There are some interesting differences between statins and PCSK9 inhibitors - for example, statins moderately reduce CRP unlike PCSK9 inhibition. Conversely, PCSK9 inhibitors reduce lipoprotein(a) whereas statins do not. As already noted in discussions below, FOURIER's CVD results (based on LDL-c reduction and trial duration) appear to match up very well with pooled CTT statin trial data despite these other differences.

Does this allow us to draw any insights regarding the importance (or perhaps lack of importance) of the effect of statins and PCSK9 inhibitors on inflammation and Lp(a)?